Kantar Health Reveals New Approach for Identifying Optimal Pricing for Complex Diseases

Share Article

Kantar Health thought leaders will present at PharmaMarket Research Conference.

Kantar Health, a leading global healthcare consulting firm, today announced that Ian McKinnon, Ph.D., chief research officer, and Debbie Warner, vice president, oncology market access, will present at the PharmaMarket Research Conference February 7 in Parsippany, N.J.

Dr. McKinnon and Ms. Warner will present “Is pricing research more difficult than herding cats…and maybe even less fruitful?” This presentation will argue that rigorous scientific methods can be used to identify the optimal pricing for multiple stakeholders. Further, the session will discuss a system dynamics model that integrates the unique impact of cost in its multiple forms on each decision maker and then determines the unified, multi-decision maker impact of price and its optimal value.

Pricing a new drug is a complex process of understanding the interplay between access challenges posed by payers, the willingness to pay of patients, and the balancing of clinical outcomes and patient costs for physicians. Complex diseases are often further subject to influences from other stakeholders, such as advocacy groups and channel members.

For more information on this event, please visit http://pharmamarketresearchconference.com/usa.html.

About Kantar Health
Kantar Health is a leading global healthcare consulting firm and trusted advisor to many pharmaceutical, biotech, and medical device and diagnostic companies worldwide. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and brand and marketing expertise to help clients evaluate opportunities, launch products and maintain brand and market leadership.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from preclinical development to launch, acting as catalysts to successful decision-making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit http://www.kantarhealth.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Stacy Sevcik
Kantar Health
+1 (314) 529-3062
Email >
since: 09/2009
Follow >
Follow us on
Visit website